We are currently living in the generation of vast volumes of data, creating new evidence which has the potential to add significantly to the way the benefit-risk of medicinal products.

The EMA and the European Union Medicines Regulatory Network are sharing this report with information on the latest developments in the field of big data from the perspective of different stakeholders. This will begin to clarify how and when the multitude of data sources may contribute to medicinal product development, authorisation and surveillance.

If you wish to have the complete information about this workshop, you could access to the entire report by clicking in the link below:

http://www.ema.europa.eu/docs/en_GB/document_library/Report/2017/02/WC500221938.pdf